Startseite Medizin Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome
Artikel Open Access

Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome

  • Darijus Skaudickas EMAIL logo , Titas Telksnys , Vincentas Veikutis , Povilas Aniulis und Mindaugas Jievaltas
Veröffentlicht/Copyright: 1. Juli 2020

Abstract

Background

Prostatitis is the most commonly diagnosed disease in men younger than 50 years and accounts for about 8% of all urologists’ consultations.

Objective

After evaluating clinical trials and demonstrating the efficacy of chronic non-bacterial prostatitis treatment, it remains of clinical importance to continue studies on the use of low-energy extracorporeal shock wave therapy (ESWT) in men.

Materials and methods

From May 2017 to April 2018, 40 patients with chronic prostatitis (CP) type IIIB/chronic pelvic pain syndrome (CPPS) were enrolled in the study. The patients underwent ESWT once a week for 4 weeks.

Results

The mean age of the patients was 47.8 years. A statistically significant improvement in all the parameters, i.e., the International Prostate Symptom Score (IPSS), the visual analogue scale (VAS), National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), and the International Index of Erectile Function (IIEF), was observed at week 4. The effect of the treatment was maintained during the entire 12-week period. The NIH-CPSI total score showed the best improvement at week 4, but a slight deterioration without a statistically significant change was noticed at week 12. The greatest improvement at week 4 was documented for the NIH-CPSI and IPSS (43% and 37%, respectively). At week 12, an improvement of 52% and 39% was recorded for VAS and IPSS, respectively.

Conclusions

Our findings confirmed the effectiveness and safety of ESWT in resistant cases of CPPS in the short term. ESWT is cost-effective, which takes little time or requires a small amount of staff, and is easily conducted.

1 Introduction

Most men, especially at younger age, experience discomfort in the small pelvic region. Recently, the number of patients suffering from chronic pelvic pain syndrome (CPPS) has been increasing [1]. Patients with chronic non-bacterial prostatitis make up the greatest percentage [2]. Prostatitis is the most commonly diagnosed disease in men younger than 50 years and accounts for about 8% of all urologists’ consultations. According to the published studies, the prevalence of prostatitis in the population ranges from 4% to 11% [3]. Episodic pelvic pain and erectile dysfunction, such as functional CPPS symptoms, mostly affect the quality of life (QoL) of men with this disease [4].

Most probably, the etiology and pathogenesis of chronic prostatitis (CP)/CPPS include a pluricausal, multifactorial mechanism. Perineal and/or pelvic trauma, infection, reflux of some toxic or immunogenic urine material, and/or psychological stress, being an initial stimulus, trigger a cascade of incidents in anatomically or genetically sensitive men, leading to a local reaction of inflammation and/or neurogenic damage. Later on, immunologic and/or neuropathic mechanisms mediated by neuroendocrine pathways propagate or maintain the chronicity of the primary event. All this results in the clinical manifestation of chronic perineal/pelvic pain symptoms related to local and central neuropathic mechanisms [5,6,7,8,9].

Prostatitis of category III, known as CP/CPPS as well, is the most prevalent type (Figure 1). According to the existing NIH description, CP/CPPS is characterized by genitourinary pain with or without voiding symptoms unaccompanied by uropathogenic bacteria. CP/CPPS is categorized into IIIA and IIIB. Category IIIA refers to the existence of any amount of white blood cells in the semen, post-prostate-massage urine sample, or expressed prostatic secretions. This matches the previously used classification of non-bacterial prostatitis. Category IIIB is similar to the before-used term prostatodynia and is characterized by pelvic pain but no inflammation in the semen [6].

Figure 1 Prostatitis classification of the NIH.
Figure 1

Prostatitis classification of the NIH.

After evaluating clinical trials and demonstrating the efficacy of this treatment, it remains of clinical importance to continue studies on the use of low-energy extracorporeal shock wave therapy (ESWT) in men. A clinical trial of such kind has not yet been performed in Lithuania.

2 Materials and methods

From May 2017 to April 2018, 40 patients with CP type IIIB/CPPS diagnosed based on the NIH International Prostatitis Collaboration Network report [10], referred to the Clinic of Urology, Lithuanian University of Health Sciences, were included in this study. All the patients provided signed informed consent. The Bioethics Centre of the Lithuanian University of Health Sciences granted approval to conduct this study (No. BEC-MF-334).

Patients underwent ESWT once a week for 4 weeks (3,000 individually with a maximum total energy flow density of 0.25 mJ/mm2, rate 3 Hz). The appliance used to treat patients in this study was a typical electromagnetic shock wave device with a focused shock wave source (Duolith model SD1, Storz Medical, Switzerland). The depth of the transducer focus zone penetration ranges from 35 to 65 mm (Figure 2). The location of the transducer was changed every 500 pulses perineally to affect the whole prostatic and pelvic floor region.

Figure 2 Characteristics of the transducer.
Figure 2

Characteristics of the transducer.

The effect of ESWT on pain, QoL, erectile function, and urination was estimated. These parameters were evaluated using the following validated questionnaires: the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Score (IPSS), the International Index of Erectile Function (IIEF), and the visual analogue scale (VAS).

Data were compared using the paired-samples t test. The statistical package IBM SPSS Statistics, version 21, was used for statistical analysis.

3 Results

The mean age of the patients was 47.8 ± 11.1 years (range 25–78). The patients were not categorized by the type of treatment they received prior to ESWT because it was very different and individual. Table 1 depicts the results of our study after treatment.

Table 1

Results: changes in parameters

ParameterP value95% CIMean differenceImprovement, %
IPSS (week 0) – IPSS (week 4)<0.0012.3 to 3.42.837
IPSS (week 0) – IPSS (week 12)<0.0012.2 to 3.93.039
IPSS (week 4) – IPSS (week 12)0.367−0.3 to 0.70.24
VAS (week 0) – VAS (week 4)<0.0010.4 to 0.70.524
VAS (week 0) – VAS (week 12)<0.0010.9 to 1.41.152
VAS (week 4) – VAS (week 12)<0.0010.4 to 0.80.638
NIH-CPSI (week 0) – NIH-CPSI (week 4) <0.0013.7 to 6.55.143
NIH-CPSI (week 0) – NIH-CPSI (week 12)<0.0012.9 to 6.24.538
NIH-CPSI (week 4) – NIH-CPSI (week 12)0.225−1.5 to 0.4−0.6−9
IIEF (week 0) – IIEF (week 4)<0.001−1.6 to −0.5−1.16
IIEF (week 0) – IIEF (week 12)<0.001−1.9 to −0.9−1.48
IIEF (week 4) – IIEF (week 12)0.230−0.9 to 0.2−0.32

IPSS, International Prostate Symptom Score; VAS, visual analogue scale; NIH-CPSI, National Institutes of Health Chronic Prostatitis Symptom Index; IIEF, the International Index of Erectile Function.

A statistically significant improvement in all the parameters, i.e., IPSS, VAS, NIH-CPSI, and IIEF, was observed at week 4. The effect of the treatment remained during the entire 12-week period. Meanwhile, the NIH-CPSI total score showed the greatest improvement at week 4, but a slight deterioration without a statistically significant change was noticed at week 12.

At week 4, the greatest improvement was documented for the NIH-CPSI and IPSS (43% and 37%, respectively). At week 12, an improvement of 52% and 39% was recorded for VAS and IPSS, respectively (Figures 3–6).

Figure 3 Changes in the total score of IPSS.
Figure 3

Changes in the total score of IPSS.

Figure 4 Changes in the VAS score for pain.
Figure 4

Changes in the VAS score for pain.

Figure 5 Changes in the NIH-CPSI.
Figure 5

Changes in the NIH-CPSI.

Figure 6 Changes in the IIEF.
Figure 6

Changes in the IIEF.

No side effects occurred in any patient through the treatment and follow-up periods.

4 Discussion

The treatment of CPPS is multidisciplinary. There are no precise treatment recommendations on how to cure this problem, which has a significant impact on the QoL not only of men but also of their partners. Urinary disorders, pain syndrome, and erectile dysfunction indirectly affect close relatives of patients. Antibiotics, analgesics, α-blockers, antiphlogistics, 5-alpha-reductase inhibitors, and homeopathic agents are used for individual combinations [11]. Physiotherapy, acupuncture, trigger-point massage, electromagnetic treatment, traditional Chinese medicine, rectal massage, thermotherapy, hyperthermia, invasive neuromodulation, balloon dilatation, laser coagulation, and intraprostatic injection of botulinum toxin A could be mentioned as alternative strategies for the treatment of CPPS [12,13].

Currently, low-energy ESWT in clinical settings is used to heal orthopedic pain syndromes, fractures, and wounds. Several mechanisms on how low-energy ESWT could affect CPPS have been proposed, namely reduction in passive muscle tone, hyperstimulation of nociceptors, blockage of the flow of nerve impulses, or the effect on the neuroplasticity of pain memory [14]. Other studies have shown that shock waves are simply applicable perineally without side effects, with a significant improvement in CPPS symptoms, especially in patients with expanding and repeating pain [15,16].

According to our literature review, Zimmermann et al. in their study [14] conducted in 2008 reported that pain and QoL considerably improved after ESWT. An improvement in voiding conditions, but not statistically significant, was also recorded. They found that only 17% of the patients showed an increase in serum the prostate specific antigen (PSA) 2 days after the treatment, and this shows that ESWT is not traumatic for the prostate gland. In our study, no pain or discomfort was documented during or after the treatment as well.

Zimmermann et al. in their later study [15] showed that all patients who underwent ESWT reported significantly reduced pain, better QoL, and improved voiding conditions as compared to the placebo group.

A study by Moayednia et al. [16] showed ESWT to be a safe and efficient procedure in patients suffering from CPPS during short-term follow-up, but no long-term efficacy of ESWT was documented. Contrary to the study by Moayednia et al. [16], Al Edwan et al. [17] reported that the long-term efficacy of ESWT remained within 12 months despite a statistically insignificant deterioration observed after 2 weeks.

In a randomized study by Yan et al. [18], involving 80 patients with CPPS, a significant improvement in the NIH-CPSI, QoL, and pain was observed in comparison with the baseline at all post-treatment results in the ESWT group.

A study by Guu et al. [19] reported extremely good results using ESWT in patients who were unsuccessfully treated with a traditional therapy previously. A total of 33 patients who received at least a 6-week trial of triple antibiotic therapy, including fluoroquinolone, alpha blocker, and acetaminophen (a non-steroidal anti-inflammatory drug), were included in the study. These patients achieved a clinically significant improvement in a short time after the ESWT therapy. The advantage of this study is that the selection criteria were homogenous. In our study, the patients were not categorized by the type of treatment they received prior to ESWT because it was very different and individual.

Pajovic et al. [20] conducted a study aiming at determining the effect of combination of ESWT and triple therapy versus triple therapy alone in patients with category IIIB CP/CPPS and showed a cumulative effect of adding ESWT to the standard treatment. Patients who were administered triple therapy showed no significant improvement in post-void residual urine and maximum flow rate (QMAX); meanwhile, the combination treatment resulted in both significantly improved post-void residual urine and QMAX values. All items of the NIH-CPSI improved statistically significantly in both groups after the treatment, but better results were documented in the group that was administered the combination of ESWT and triple therapy.

In our study, a significant improvement in the IPSS, VAS, NIH-CPSI, and IIEF was documented at week 4. The efficiency of the treatment was retained during the whole period of 12 weeks. Pain that is considered the main parameter deteriorating the QoL was significantly reduced in this study.

5 Conclusions

In conclusion, our findings confirmed the effectiveness and safety of ESWT in resistant cases of CPPS in the short term. ESWT is cost-effective, which takes little time or requires a small amount of staff, is easy to conduct, and prevents systemic adverse effects. ESWT is a local therapy with the opportunity of repeating the treatment at any time. Furthermore, large-scale and long-term studies are required to compare the efficacy of and to describe a standard protocol for ESWT.

The limitations of the design of our study are that there is no randomized controlled group and that our study is a non-blinded single-arm clinical trial. We are thinking that ESWT may have psychologically affected the clinical outcome.

Furthermore, large-scale and long-term studies with a control group are required to compare the efficacy of and to describe a standard protocol for ESWT.

  1. Conflicts of interest: Authors state no conflict of interest.

References

[1] Collins MM, Stafford RS, O’Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998;159(4):1224–8.10.1016/S0022-5347(01)63564-XSuche in Google Scholar

[2] Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2004;172(3):839–45.10.1097/01.ju.0000136002.76898.04Suche in Google Scholar

[3] Chen X, Zhou Z, Qiu X, Wang B, Dai J. The effect of chronic prostatitis on erectile dysfunction. PLoS One. 2015;10(10):e0141447.10.1371/journal.pone.0141447Suche in Google Scholar

[4] Peciulyte G, Jonusiene G, Skaudickas D. PS-01-017 evaluation of personality traits, sexual function, and prevalence of masturbation in men with chronic prostatitis/chronic pelvic pain syndrome. J Sex Med. 2016;13(5):S81–S82.10.1016/j.jsxm.2016.03.365Suche in Google Scholar

[5] Nickel JC. Prostatitis and related conditions, orchitis, and epididymitis. In: Wein AJ, Kavoussi LR, Partin AW, Novick AC, Peters CA, editors. Campbell–Walsh urology. 10th ed. Philadelphia: Saunders; 2012. p. 333.10.1016/B978-1-4160-6911-9.00011-6Suche in Google Scholar

[6] Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999;54(2):229–33.10.1016/S0090-4295(99)00205-8Suche in Google Scholar

[7] Chiechio S, Zammataro M, Caraci F, Rampello L, Copani A, Sabato AF, et al. Pregabalin in the treatment of chronic pain: an overview. Clin Drug Investig. 2009;29:203–13.10.2165/00044011-200929030-00006Suche in Google Scholar

[8] Tripp DA, Curtis Nickel J, Landis JR, Wang YL, Knauss JS, CPCRN Study Group. Predictors of quality of life and pain in chronic prostatitis/chronic pelvic pain syndrome: findings from the National Institutes of Health Chronic Prostatitis Cohort Study. BJU Int. 2004;94(9):1279–82.10.1111/j.1464-410X.2004.05157.xSuche in Google Scholar

[9] Tripp DA, Nickel JC, Shoskes D, Koljuskov A. A 2-year follow-up of quality of life, pain, and psychosocial factors in patients with chronic prostatitis/chronic pelvic pain syndrome and their spouses. World J Urol. 2013;31(4):733–9.10.1007/s00345-013-1067-6Suche in Google Scholar

[10] Nickel JC, Nyberg LM, Hennenfent M. Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology. 1999;54(2):229–33.10.1016/S0090-4295(99)00205-8Suche in Google Scholar

[11] Wein AJ, Kavoussi LR, Novick AC, Partin AW, editors. Campbell–Walsh Urology. 10th ed. Philadelphia, PA, USA: Saunders; 2012.10.1016/B978-1-4160-6911-9.00147-XSuche in Google Scholar

[12] Giubilei G, Mondaini N, Minervini A, Saieva C, Lapini A, Serni S, et al. Physical activity of men with chronic prostatitis/chronic pelvic pain syndrome not satisfied with conventional treatments – could it represent a valid option? The physical activity and male pelvic pain trial: a double blind, randomized trial. J Urol. 2007;177:159–65.10.1016/j.juro.2006.08.107Suche in Google Scholar PubMed

[13] Nickel JC, Sorensen R. Transurethral microwave thermotherapy for nonbacterial prostatitis: a randomized double-blind sham controlled study using new prostatitis specific assessment questionnaires. J Urol. 1996;155:1950–4.10.1097/00005392-199606000-00036Suche in Google Scholar

[14] Zimmermann R, Cumpanas A, Hoeltl L, Janetschek G, Stenzl A, Miclea F. Extracorporeal shock-wave therapy for treating chronic pelvic pain syndrome: a feasibility study and the first clinical results. BJU Int. 2008;102:976–80.10.1111/j.1464-410X.2008.07742.xSuche in Google Scholar PubMed

[15] Zimmermann R, Cumpanas A, Miclea F, Janetschek G. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomised, double blind, placebo-controlled study. Eur Urol. 2009;56:418–24.10.1016/j.eururo.2009.03.043Suche in Google Scholar PubMed

[16] Moayednia A, Haghdani S, Khosrawi S, Yousefi E, Vahdatpour B. Long-term effect of extracorporeal shock wave therapy on the treatment of chronic pelvic pain syndrome due to non bacterial prostatitis. J Res Med Sci. 2014;19(4):293–6.Suche in Google Scholar

[17] Al Edwan GM, Muheilan MM, Atta ON. Long term efficacy of extracorporeal shock wave therapy [ESWT] for treatment of refractory chronic abacterial prostatitis. Ann Med Surg. 2017;14:12–7.10.1016/j.amsu.2016.12.051Suche in Google Scholar PubMed PubMed Central

[18] Yan X, Yang G, Cheng L, Chen M, Cheng X, Chai Y, et al. Effect of extracorporeal shock wave therapy on diabetic chronic wound healing and its histological features. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012;26:961–7.Suche in Google Scholar

[19] Guu SJ, Geng JH, Chao IT, Lin HT, Lee YC, Juan YS, et al. Efficacy of low intensity extracorporeal shock wave therapy on men with chronic pelvic pain syndrome refractory to 3-as therapy. Am J Mens Health. 2018;12(2):441–52.10.1177/1557988317736585Suche in Google Scholar PubMed PubMed Central

[20] Pajovic B, Radojevic N, Dimitrovski A, Vukovic M. Comparison of the efficiency of combined extracorporeal shock-wave therapy and triple therapy versus triple therapy itself in category III B chronic pelvic pain syndrome (CPPS). Aging Male. 2016;19(3):202–7, Epub 2016 Jul 5.10.1080/13685538.2016.1197899Suche in Google Scholar PubMed

Received: 2019-08-08
Revised: 2020-01-27
Accepted: 2020-05-08
Published Online: 2020-07-01

© 2020 Darijus Skaudickas et al., published by De Gruyter

This work is licensed under the Creative Commons Attribution 4.0 International License.

Artikel in diesem Heft

  1. Research Article
  2. MicroRNA-451b participates in coronary heart disease by targeting VEGFA
  3. Case Report
  4. A combination therapy for Kawasaki disease with severe complications: a case report
  5. Vitamin E for prevention of biofilm-caused Healthcare-associated infections
  6. Research Article
  7. Differential diagnosis: retroperitoneal fibrosis and oncological diseases
  8. Optimization of the Convolutional Neural Networks for Automatic Detection of Skin Cancer
  9. NEAT1 promotes LPS-induced inflammatory injury in macrophages by regulating miR-17-5p/TLR4
  10. Plasma matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 as prognostic biomarkers in critically ill patients
  11. Effects of extracorporeal magnetic stimulation in fecal incontinence
  12. Case Report
  13. Mixed germ cell tumor of the endometrium: a case report and literature review
  14. Bowel perforation after ventriculoperitoneal-shunt placement: case report and review of the literature
  15. Research Article
  16. Prognostic value of lncRNA HOTAIR in colorectal cancer : a meta-analysis
  17. Case Report
  18. Treatment of insulinomas by laparoscopic radiofrequency ablation: case reports and literature review
  19. Research Article
  20. The characteristics and nomogram for primary lung papillary adenocarcinoma
  21. Undiagnosed pheochromocytoma presenting as a pancreatic tumor: A case report
  22. Bioinformatics Analysis of the Expression of ATP binding cassette subfamily C member 3 (ABCC3) in Human Glioma
  23. Diagnostic value of recombinant heparin-binding hemagglutinin adhesin protein in spinal tuberculosis
  24. Primary cutaneous DLBCL non-GCB type: challenges of a rare case
  25. LINC00152 knock-down suppresses esophageal cancer by EGFR signaling pathway
  26. Case Report
  27. Life-threatening anaemia in patient with hereditary haemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)
  28. Research Article
  29. QTc interval predicts disturbed circadian blood pressure variation
  30. Shoulder ultrasound in the diagnosis of the suprascapular neuropathy in athletes
  31. The number of negative lymph nodes is positively associated with survival in esophageal squamous cell carcinoma patients in China
  32. Differentiation of pontine infarction by size
  33. RAF1 expression is correlated with HAF, a parameter of liver computed tomographic perfusion, and may predict the early therapeutic response to sorafenib in advanced hepatocellular carcinoma patients
  34. LncRNA ZEB1-AS1 regulates colorectal cancer cells by miR-205/YAP1 axis
  35. Tissue coagulation in laser hemorrhoidoplasty – an experimental study
  36. Classification of pathological types of lung cancer from CT images by deep residual neural networks with transfer learning strategy
  37. Enhanced Recovery after Surgery for Lung Cancer Patients
  38. Case Report
  39. Streptococcus pneumoniae-associated thrombotic microangiopathy in an immunosuppressed adult
  40. Research Article
  41. The characterization of Enterococcus genus: resistance mechanisms and inflammatory bowel disease
  42. Case Report
  43. Inflammatory fibroid polyp: an unusual cause of abdominal pain in the upper gastrointestinal tract A case report
  44. Research Article
  45. microRNA-204-5p participates in atherosclerosis via targeting MMP-9
  46. LncRNA LINC00152 promotes laryngeal cancer progression by sponging miR-613
  47. Can keratin scaffolds be used for creating three-dimensional cell cultures?
  48. miRNA-186 improves sepsis induced renal injury via PTEN/PI3K/AKT/P53 pathway
  49. Case Report
  50. Delayed bowel perforation after routine distal loopogram prior to ileostomy closure
  51. Research Article
  52. Diagnostic accuracy of MALDI-TOF mass spectrometry for the direct identification of clinical pathogens from urine
  53. The R219K polymorphism of the ATP binding cassette subfamily A member 1 gene and susceptibility to ischemic stroke in Chinese population
  54. miR-92 regulates the proliferation, migration, invasion and apoptosis of glioma cells by targeting neogenin
  55. Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma
  56. NF2 inhibits proliferation and cancer stemness in breast cancer
  57. Body composition indices and cardiovascular risk in type 2 diabetes. CV biomarkers are not related to body composition
  58. S100A6 promotes proliferation and migration of HepG2 cells via increased ubiquitin-dependent degradation of p53
  59. Review Article
  60. Focus on localized laryngeal amyloidosis: management of five cases
  61. Research Article
  62. NEAT1 aggravates sepsis-induced acute kidney injury by sponging miR-22-3p
  63. Pericentric inversion in chromosome 1 and male infertility
  64. Increased atherogenic index in the general hearing loss population
  65. Prognostic role of SIRT6 in gastrointestinal cancers: a meta-analysis
  66. The complexity of molecular processes in osteoarthritis of the knee joint
  67. Interleukin-6 gene −572 G > C polymorphism and myocardial infarction risk
  68. Case Report
  69. Severe anaphylactic reaction to cisatracurium during anesthesia with cross-reactivity to atracurium
  70. Research Article
  71. Rehabilitation training improves nerve injuries by affecting Notch1 and SYN
  72. Case Report
  73. Myocardial amyloidosis following multiple myeloma in a 38-year-old female patient: A case report
  74. Research Article
  75. Identification of the hub genes RUNX2 and FN1 in gastric cancer
  76. miR-101-3p sensitizes non-small cell lung cancer cells to irradiation
  77. Distinct functions and prognostic values of RORs in gastric cancer
  78. Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy
  79. Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
  80. Review Article
  81. The role of osteoprotegerin in the development, progression and management of abdominal aortic aneurysms
  82. Research Article
  83. Identification of key microRNAs of plasma extracellular vesicles and their diagnostic and prognostic significance in melanoma
  84. miR-30a-3p participates in the development of asthma by targeting CCR3
  85. microRNA-491-5p protects against atherosclerosis by targeting matrix metallopeptidase-9
  86. Bladder-embedded ectopic intrauterine device with calculus
  87. Case Report
  88. Mycobacterial identification on homogenised biopsy facilitates the early diagnosis and treatment of laryngeal tuberculosis
  89. Research Article
  90. The will of young minors in the terminal stage of sickness: A case report
  91. Extended perfusion protocol for MS lesion quantification
  92. Identification of four genes associated with cutaneous metastatic melanoma
  93. Case Report
  94. Thalidomide-induced serious RR interval prolongation (longest interval >5.0 s) in multiple myeloma patient with rectal cancer: A case report
  95. Research Article
  96. Voluntary exercise and cardiac remodeling in a myocardial infarction model
  97. Electromyography as an intraoperative test to assess the quality of nerve anastomosis – experimental study on rats
  98. Case Report
  99. CT findings of severe novel coronavirus disease (COVID-19): A case report of Heilongjiang Province, China
  100. Commentary
  101. Directed differentiation into insulin-producing cells using microRNA manipulation
  102. Research Article
  103. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality
  104. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome
  105. Plasma microRNAs in human left ventricular reverse remodelling
  106. Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis
  107. Risk factors for cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage
  108. Problems and solutions of personal protective equipment doffing in COVID-19
  109. Evaluation of COVID-19 based on ACE2 expression in normal and cancer patients
  110. Review Article
  111. Gastroenterological complications in kidney transplant patients
  112. Research Article
  113. CXCL13 concentration in latent syphilis patients with treatment failure
  114. A novel age-biomarker-clinical history prognostic index for heart failure with reduced left ventricular ejection fraction
  115. Case Report
  116. Clinicopathological analysis of composite lymphoma: A two-case report and literature review
  117. Trastuzumab-induced thrombocytopenia after eight cycles of trastuzumab treatment
  118. Research Article
  119. Inhibition of vitamin D analog eldecalcitol on hepatoma in vitro and in vivo
  120. CCTs as new biomarkers for the prognosis of head and neck squamous cancer
  121. Effect of glucagon-like peptide-1 receptor agonists on adipokine level of nonalcoholic fatty liver disease in rats fed high-fat diet
  122. 72 hour Holter monitoring, 7 day Holter monitoring, and 30 day intermittent patient-activated heart rhythm recording in detecting arrhythmias in cryptogenic stroke patients free from arrhythmia in a screening 24 h Holter
  123. FOXK2 downregulation suppresses EMT in hepatocellular carcinoma
  124. Case Report
  125. Total parenteral nutrition-induced Wernicke’s encephalopathy after oncologic gastrointestinal surgery
  126. Research Article
  127. Clinical prediction for outcomes of patients with acute-on-chronic liver failure associated with HBV infection: A new model establishment
  128. Case Report
  129. Combination of chest CT and clinical features for diagnosis of 2019 novel coronavirus pneumonia
  130. Research Article
  131. Clinical significance and potential mechanisms of miR-223-3p and miR-204-5p in squamous cell carcinoma of head and neck: a study based on TCGA and GEO
  132. Review Article
  133. Hemoperitoneum caused by spontaneous rupture of hepatocellular carcinoma in noncirrhotic liver. A case report and systematic review
  134. Research Article
  135. Voltage-dependent anion channels mediated apoptosis in refractory epilepsy
  136. Prognostic factors in stage I gastric cancer: A retrospective analysis
  137. Circulating irisin is linked to bone mineral density in geriatric Chinese men
  138. Case Report
  139. A family study of congenital dysfibrinogenemia caused by a novel mutation in the FGA gene: A case report
  140. Research Article
  141. CBCT for estimation of the cemento-enamel junction and crestal bone of anterior teeth
  142. Case Report
  143. Successful de-escalation antibiotic therapy using cephamycins for sepsis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia: A sequential 25-case series
  144. Research Article
  145. Influence factors of extra-articular manifestations in rheumatoid arthritis
  146. Assessment of knowledge of use of electronic cigarette and its harmful effects among young adults
  147. Predictive factors of progression to severe COVID-19
  148. Procedural sedation and analgesia for percutaneous trans-hepatic biliary drainage: Randomized clinical trial for comparison of two different concepts
  149. Acute chemoradiotherapy toxicity in cervical cancer patients
  150. IGF-1 regulates the growth of fibroblasts and extracellular matrix deposition in pelvic organ prolapse
  151. NANOG regulates the proliferation of PCSCs via the TGF-β1/SMAD pathway
  152. An immune-relevant signature of nine genes as a prognostic biomarker in patients with gastric carcinoma
  153. Computer-aided diagnosis of skin cancer based on soft computing techniques
  154. MiR-1225-5p acts as tumor suppressor in glioblastoma via targeting FNDC3B
  155. miR-300/FA2H affects gastric cancer cell proliferation and apoptosis
  156. Hybrid treatment of fibroadipose vascular anomaly: A case report
  157. Surgical treatment for common hepatic aneurysm. Original one-step technique
  158. Neuropsychiatric symptoms, quality of life and caregivers’ burden in dementia
  159. Predictor of postoperative dyspnea for Pierre Robin Sequence infants
  160. Long non-coding RNA FOXD2-AS1 promotes cell proliferation, metastasis and EMT in glioma by sponging miR-506-5p
  161. Analysis of expression and prognosis of KLK7 in ovarian cancer
  162. Circular RNA circ_SETD2 represses breast cancer progression via modulating the miR-155-5p/SCUBE2 axis
  163. Glial cell induced neural differentiation of bone marrow stromal cells
  164. Case Report
  165. Moraxella lacunata infection accompanied by acute glomerulonephritis
  166. Research Article
  167. Diagnosis of complication in lung transplantation by TBLB + ROSE + mNGS
  168. Case Report
  169. Endometrial cancer in a renal transplant recipient: A case report
  170. Research Article
  171. Downregulation of lncRNA FGF12-AS2 suppresses the tumorigenesis of NSCLC via sponging miR-188-3p
  172. Case Report
  173. Splenic abscess caused by Streptococcus anginosus bacteremia secondary to urinary tract infection: a case report and literature review
  174. Research Article
  175. Advances in the role of miRNAs in the occurrence and development of osteosarcoma
  176. Rheumatoid arthritis increases the risk of pleural empyema
  177. Effect of miRNA-200b on the proliferation and apoptosis of cervical cancer cells by targeting RhoA
  178. LncRNA NEAT1 promotes gastric cancer progression via miR-1294/AKT1 axis
  179. Key pathways in prostate cancer with SPOP mutation identified by bioinformatic analysis
  180. Comparison of low-molecular-weight heparins in thromboprophylaxis of major orthopaedic surgery – randomized, prospective pilot study
  181. Case Report
  182. A case of SLE with COVID-19 and multiple infections
  183. Research Article
  184. Circular RNA hsa_circ_0007121 regulates proliferation, migration, invasion, and epithelial–mesenchymal transition of trophoblast cells by miR-182-5p/PGF axis in preeclampsia
  185. SRPX2 boosts pancreatic cancer chemoresistance by activating PI3K/AKT axis
  186. Case Report
  187. A case report of cervical pregnancy after in vitro fertilization complicated by tuberculosis and a literature review
  188. Review Article
  189. Serrated lesions of the colon and rectum: Emergent epidemiological data and molecular pathways
  190. Research Article
  191. Biological properties and therapeutic effects of plant-derived nanovesicles
  192. Case Report
  193. Clinical characterization of chromosome 5q21.1–21.3 microduplication: A case report
  194. Research Article
  195. Serum calcium levels correlates with coronary artery disease outcomes
  196. Rapunzel syndrome with cholangitis and pancreatitis – A rare case report
  197. Review Article
  198. A review of current progress in triple-negative breast cancer therapy
  199. Case Report
  200. Peritoneal-cutaneous fistula successfully treated at home: A case report and literature review
  201. Research Article
  202. Trim24 prompts tumor progression via inducing EMT in renal cell carcinoma
  203. Degradation of connexin 50 protein causes waterclefts in human lens
  204. GABRD promotes progression and predicts poor prognosis in colorectal cancer
  205. The lncRNA UBE2R2-AS1 suppresses cervical cancer cell growth in vitro
  206. LncRNA FOXD3-AS1/miR-135a-5p function in nasopharyngeal carcinoma cells
  207. MicroRNA-182-5p relieves murine allergic rhinitis via TLR4/NF-κB pathway
Heruntergeladen am 31.12.2025 von https://www.degruyterbrill.com/document/doi/10.1515/med-2020-0174/html
Button zum nach oben scrollen